Digesting the genetics of inflammatory bowel disease: Insights from studies of autophagy risk genes

Inflammatory Bowel Diseases

Volumn 18, Issue 4, 2012, Pages 782-792

  Kabi, Amrita ^a   Nickerson, Kourtney P ^a,b   Homer, Craig R ^a   McDonald, Christine ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibacterial response; Autophagy; Crohn's disease; Inflammatory bowel disease; Mucosal immunology

Indexed keywords

AMIODARONE; ASCORBIC ACID; ATG16L1 PROTEIN; COLECALCIFEROL; CURCUMIN; EVEROLIMUS; FLUSPIRILENE; GENISTEIN; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; LOPERAMIDE; MEMBRANE PROTEIN; NICARDIPINE; NICLOSAMIDE; NIGULDIPINE; PERHEXILINE; PIMOZIDE; QUERCETIN; RAPAMYCIN; RESVERATROL; TRIFLUOPERAZINE; ULK1 PROTEIN; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ANGINA PECTORIS; ANTIBACTERIAL ACTIVITY; AUTOPHAGOSOME; AUTOPHAGY; BACTERIAL INFECTION; BRAIN CANCER; CELL COMPONENT; CHRONIC INFLAMMATION; COLON CANCER; COLORECTAL CANCER; CROHN DISEASE; DIARRHEA; ENTERITIS; GENETIC ANALYSIS; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HUMAN; HUNTINGTON CHOREA; HYPERTENSION; HYPOTHESIS; INFECTION CONTROL; INNATE IMMUNITY; INTESTINE FLORA; LUNG CANCER; LYMPHOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PSYCHOSIS; RAYNAUD PHENOMENON; REVIEW; SALIVARY GLAND CANCER; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

AUTOPHAGY; CARRIER PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GTP-BINDING PROTEINS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; NOD2 SIGNALING ADAPTOR PROTEIN; PHAGOSOMES; POLYMORPHISM, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, CALCITRIOL; RISK;

EID: 84858709627     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21868     Document Type: Review

References (82)

1. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246-252.
2. Franke A, McGovern DP, Barrett, JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118-1125.
3. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology. 2011;140:1704-1712.
4. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009;43:67-93.
5. Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med. 2010;16:90-97.
6. Homer CR, Richmond AL, Rebert NA, et al. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. Gastroenterology. 2010;139:1630-1641.
7. Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol. 2010;11:55-62.
8. Sumpter R Jr, Levine B. Autophagy and innate immunity: triggering, targeting and tuning. Semin Cell Dev Biol. 2010;21:699-711.
9. Weidberg H, Shvets E, Elazar Z. Biogenesis and cargo selectivity of autophagosomes. Annu Rev Biochem. 2011;80:125-156.
10. Massey DC, Parkes M. Genome-wide association scanning highlights two autophagy genes, ATG16L1 and IRGM, as being significantly associated with Crohn's disease. Autophagy. 2007;3:649-651. (Pubitemid 350060072)
11. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet. 2007;39:830-832. (Pubitemid 47014496)
12. Roberts RL, Hollis-Moffatt JE, Gearry RB, et al. Confirmation of association of IRGM and NCF4 with ileal Crohn's disease in a population- based cohort. Genes Immun. 2008;9:561-565.
13. Simmons JD, Mullighan C, Welsh KI, et al. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut. 2000;47:211-214. (Pubitemid 30489764)
14. Koren I, Reem E, Kimchi A. DAP1, a novel substrate of mTOR, negatively regulates autophagy. Curr Biol. 2010;20:1093-1098.
15. Kuester D, Guenther T, Biesold S, et al. Aberrant methylation of DAPK in long-standing ulcerative colitis and ulcerative colitis-associated carcinoma. Pathol Res Pract. 2010;206:616-624.
16. Henckaerts L, Cleynen I, Brinar M, et al. Genetic variation in the autophagy gene ULK1 and risk of Crohn's disease. Inflamm Bowel Dis. 2010;17:1392-1397.
17. Cummings JR, Cooney R, Pathan S, et al. Confirmation of the role of ATG16L1 as a Crohn's disease susceptibility gene. Inflamm Bowel Dis. 2007;13:941-946. (Pubitemid 47309964)
18. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007;39:596-604. (Pubitemid 46676115)
19. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40:955-962.
20. The Welcome Trust Case Control Consortium, Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-678.
21. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007;39:207-211. (Pubitemid 46184351)
22. Fujita N, Itoh T, Omori H, et al. The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy. Mol Biol Cell. 2008;19:2092-2100.
23. Kuballa P, Huett A, Rioux JD, et al. Impaired autophagy of an intracellular pathogen induced by a Crohn's disease associated ATG16L1 variant. PLoS One. 2008;3:e3391.
24. Lapaquette P, Glasser AL, Huett A, et al. Crohn's disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly. Cell Microbiol. 2009;12:99-113.
25. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140:1720-1728.
26. Macfarlane GT, Blackett KL, Nakayama T, et al. The gut microbiota in inflammatory bowel disease. Curr Pharm Des. 2009;15:1528-1536.
27. Saitoh T, Fujita N, Jang MH, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature. 2008;456:264-268.
28. Komatsu M, Waguri S, Ueno T, et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol. 2005;169:425-434. (Pubitemid 40686693)
29. Kuma A, Hatano M, Matsui M, et al. The role of autophagy during the early neonatal starvation period. Nature. 2004;432:1032-1036. (Pubitemid 40052234)
30. Plantinga TS, Crisan TO, Oosting M, et al. Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut. 2011;60:1229-1235.
31. Cadwell K, Liu JY, Brown SL, et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature. 2008;456:259-263.
32. Schaffler A, Herfarth H. Creeping fat in Crohn's disease: travelling in a creeper lane of research? Gut. 2005;54:742-744. (Pubitemid 40732083)
33. Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell. 2010;141:1135-1145.
34. Cho JH, Abraham C. Inflammatory bowel disease genetics: Nod2. Annu Rev Med. 2007;58:401-516.
35. Totemeyer S, Sheppard M, Lloyd A, et al. IFN-gamma enhances production of nitric oxide from macrophages via a mechanism that depends on nucleotide oligomerization domain-2. J Immunol. 2006;176:4804-4810.
36. Biswas A, Liu YJ, Hao L, et al. Induction and rescue of Nod2- dependent Th1-driven granulomatous inflammation of the ileum. Proc Natl Acad Sci U S A. 2010;107:14739-14744.
37. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731-734. (Pubitemid 40194644)
38. Petnicki-Ocwieja T, Hrncir T, Liu YJ, et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci U S A. 2009;106:15813-15818.
39. Frank DN, Robertson CE, Hamm CM, et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:179-184.
40. Schmid M, Fellermann K, Wehkamp J, et al. The role of defensins in the pathogenesis of chronic-inflammatory bowel disease. Z Gastroenterol. 2004;42:333-338. (Pubitemid 38702365)
41. Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut. 2004;53:1658-16564.
42. Barnich N, Aguirre JE, Reinecker HC, et al. Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-kappaB activation in muramyl dipeptide recognition. J Cell Biol. 2005;170:21-26. (Pubitemid 40994092)
43. Lecine P, Esmiol S, Metais JY, et al. The NOD2-RICK complex signals from the plasma membrane. J Biol Chem. 2007;282:15197-15207. (Pubitemid 47093378)
44. Chaturvedi A, Dorward D, Pierce SK. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity. 2008;28:799-809.
45. Lee HK, Lund JM, Ramanathan B, et al. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science. 2007;315:1398-1401. (Pubitemid 46399546)
46. Bekpen C, Xavier RJ, Eichler EE. Human IRGM gene "to be or not to be." Semin Immunopathol. 2009;32:437-444.
47. Singh SB, Davis AS, Taylor GA, et al. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science. 2006;313:1438-1441. (Pubitemid 44360272)
48. MacMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science. 2003;302:654-659. (Pubitemid 37310923)
49. Brest P, Lapaquette P, Souidi M, et al. A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet. 2011;43:242-245.
50. McCarroll SA, Huett A, Kuballa P, et al. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet. 2008;40:1107-1112.
51. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44:595-600. (Pubitemid 39531224)
52. Zhang Z, Burgunder JM, An X, et al. LRRK2 R1628P variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. Mov Disord. 2009;24:1902-1905.
53. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601-607. (Pubitemid 39531225)
54. Gardet A, Benita Y, Li C, et al. LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol. 2011;185:5577-5585.
55. Hakimi M, Selvanantham T, Swinton E, et al. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm. 2011;118:795-808.
56. Alegre-Abarrategui J, Christian H, Lufino MM, et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet. 2009;18:4022-4034.
57. Kim J, Kundu M, Viollet B, et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132-141.
58. Lee JW, Park S, Takahashi Y, et al. The association of AMPK with ULK1 regulates autophagy. PLoS One. 2010;5:e15394.
59. Dresner-Pollak R, Ackerman Z, Eliakim R, et al. The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients. Genet Test. 2004;8:417-420. (Pubitemid 40083108)
60. Naderi N, Farnood A, Habibi M, et al. Association of vitamin D receptor gene polymorphisms in Iranian patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2008;23:1816-1822.
61. Pei FH, Wang YJ, Gao SL, et al. Vitamin D receptor gene polymorphism and ulcerative colitis susceptibility in Han Chinese. J Dig Dis. 2011;12:90-98.
62. Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol. 2006;92:60-64. (Pubitemid 43831951)
63. Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol. 2007;8:5.
64. Froicu M, Weaver V, Wynn TA, et al. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol. 2003;17:2386-2392. (Pubitemid 37542204)
65. Froicu M, Zhu Y, Cantorna MT. Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. Immunology. 2006;117:310-318.
66. Kong J, Zhang Z, Musch MW, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol. 2008;294:G208-216.
67. Wu S, Sun J. Vitamin D, vitamin D receptor, and macroautophagy in inflammation and infection. Discov Med. 2011;11:325-335.
68. Wang TT, Dabbas B, Laperriere D, et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem. 2010;285:2227-2231.
69. Ramagopalan SV, Heger A, Berlanga AJ, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 2010;20:1352-1360.
70. Fleming A, Noda T, Yoshimori T, et al. Chemical modulators of autophagy as biological probes and potential therapeutics. Nat Chem Biol. 2011;7:9-17.
71. Balgi AD, Fonseca BD, Donohue E, et al. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One. 2009;4:e7124.
72. Zhang L, Yu J, Pan H, et al. Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc Natl Acad Sci U S A. 2007;104:19023-19028.
73. Singletary K, Milner J. Diet, autophagy, and cancer: a review. Cancer Epidemiol Biomarkers Prev. 2008;17:1596-1610.
74. Matsuda C, Ito T, Song J, et al. Therapeutic effect of a new immuno-suppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis. Clin Exp Immunol. 2007;148:348-359. (Pubitemid 46587591)
75. Dumortier J, Lapalus MG, Guillaud O, et al. Everolimus for refractory Crohn's disease: a case report. Inflamm Bowel Dis. 2008;14:874-847.
76. Massey DC, Bredin F, Parkes M. Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut. 2008;57:1294-1296.
77. Reinisch W, Panes J, Lemann M, et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to- severe active Crohn's disease. Am J Gastroenterol. 2008;103:2284-2292.
78. Cantorna MT, Munsick C, Bemiss C, et al. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr. 2000;130:2648-2652.
79. Laverny G, Penna G, Vetrano S, et al. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol Lett. 2010;131:49-58.
80. Lagishetty V, Misharin AV, Liu NQ, et al. Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis. Endocrinology. 2010;151:2423-2432.
81. Miheller P, Muzes G, Hritz I, et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis. 2009;15:1656-1662.
82. Jorgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease-a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32:377-383.